SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trading in focus as investors weigh the potential legislative impact of a bipartisan Senate bill aimed at restricting sports betting on prediction market platforms. While bulls view the proposed regulation as a competitive moat for licensed sportsbooks, the stock remains a point of contention among the community due to ongoing insider selling activity and the company's struggle to maintain positive momentum.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility and intense retail interest driven by its exposure to high-profile AI and tech unicorns like SpaceX, OpenAI, and Anthropic. The community is actively debating the sustainability of its massive premium over Net Asset Value, with many investors comparing it to similar funds while some traders attempt to navigate the stock's low float and limited share availability.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense backlash and investor frustration following a 1-for-12 reverse stock split that has left many shareholders deep in the red and questioning management's long-term strategy. The community is heavily focused on the company's lack of transparent communication, stagnant performance, and the perceived abandonment of retail investors in favor of Disney's controlling stake.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is experiencing intense selling pressure and high volatility, fueled by investor anxiety over the company's heavy AI capital expenditures, the potential impact of competing AI models like Anthropic's Claude on legacy software, and a perceived lack of clear communication from leadership. While the community is deeply divided between those viewing the steep decline as a generational buying opportunity and those fearing a prolonged downtrend, many are actively scrutinizing the stock's recent decoupling from broader market indices.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending as investors react to the company's strategic shift toward a fabless semiconductor model and the unveiling of its first in-house AGI CPU chip, which targets massive revenue growth in the AI data center market. The community is actively debating the stock's long-term potential as a primary AI infrastructure play, with many bullish investors viewing the recent volatility and price corrections as an attractive entry point for a firm now diversifying beyond traditional mobile licensing.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing a wave of bullish sentiment driven by the resignation of a key FDA official and the upcoming release of pivotal Phase 1/2 clinical data for its siRNA pipeline targeting DM1 and FSHD. Community members are focusing on these potential catalysts to drive a short-term reversal, while many investors maintain a long-term outlook anchored by the company's established commercial products and the transformative potential of its rare disease pipeline.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention from retail traders who view it as a accessible proxy for private tech giants like SpaceX, Anthropic, and OpenAI, leading to intense debate over its premium valuation relative to net asset value. While proponents highlight the massive growth potential of its underlying portfolio, skeptical community members frequently caution against the stock's volatility and the risks associated with its structure as a closed-end fund.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant market volatility following a Complete Response Letter from the FDA that rejected its drug relacorilant for the treatment of hypercortisolism, citing a need for additional evidence of effectiveness. While the company's established Cushing's syndrome franchise and ongoing oncology pipeline remain points of focus, the community is actively debating whether the steep decline represents a terminal breakdown in management credibility or a tactical buying opportunity for a cash-rich, profitable company.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is currently facing downward pressure following a short-seller report alleging channel stuffing, with the community actively debating whether to buy the dip or exit based on the perceived quality of management's initial response. Long-term investors are pointing to the company's fundamentals and ongoing share buyback program as evidence that the allegations are a misrepresentation aimed at driving profit for short-sellers.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing downward pressure amid broader market volatility and geopolitical concerns, with community sentiment split between investors viewing the current dip as a buying opportunity and traders emphasizing bearish technical setups. Discussions are heavily focused on the company's aggressive infrastructure spending, the performance of its Gemini AI integration, and lingering uncertainty regarding potential regulatory impacts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

Myriad Genetics (NASDAQ:MYGN) CEO Buys 40,000 Shares

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of the stock in a transaction on Monday, March 9th. The shares were bought at an average price of $5.00 per...

Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of Myriad Genetics stock in a transaction on Monday, March 9th. The shares were purchased at an average...

Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN

Royce & Associates LP acquired a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and...

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "Hold" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports...

S. Louise Phanstiel Buys 48,000 Shares of Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel bought 48,000 shares of the company's stock in a transaction dated Friday, February 27th. The shares were purchased...

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research

Zacks Research raised Myriad Genetics from a "strong sell" rating to a "hold" rating in a research report on Thursday...

Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel purchased 48,000 shares of the business's stock in a transaction dated Friday, February 27th. The shares were...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

MYGN
Myriad Genetics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MYGN News

MYGNMyriad Genetics, Inc.